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Abstract
We report a case of successful treatment of postoperative saphenectomy wound infection of the
upper left leg with the antibiotic drug Daptomycin.
Introduction
Since its first clinical use by Rene Favaloro in the 60's, the
great saphenous vein has become the most commonly
harvested conduit for revascularization in coronary artery
bypass grafting (CABG) [1]. In order to reduce morbidity
and improve the recovery time associated with CABG pro-
cedures, various techniques have been developed includ-
ing conventional conduit harvesting, minimally invasive
and/or endoscopic harvesting procedures [2]. Still, these
surgical techniques are associated with significant compli-
cation rates e.g. wound infections, non-infective wound
healing disturbances, postoperative pain, etc. [3]. Avoid-
ing and/or reducing these complication rates is of great
medical and economic interest. Improvements would
result in increased postoperative mobility and quality of
life as well as reduced length of hospital stay following
surgery resulting large cost savings. Although much
research has focused on comparing less invasive and con-
ventional harvest techniques, there is at present no con-
sensus on the areas of postoperative antibiotic drug
treatment of saphenectomy wound infections once an
infection occurs. Further studies are required to compare
treatment methods of saphenectomy wound infections by
different antibiotic drugs. Although, Daptomycin has
already been proven to be effective in the treatment of
bacteremia and endocarditis [4,5] caused by methilin-
resistent Staphylococcus aureus [6,7] and several case
reports about its effectiveness in the field of cardiac sur-
gery exist in the literature [8], there are still no cases
describing the successful treatment of saphenectomy
wound infections by Daptomycin.
Therefore, in this paper we report the first case of success-
ful treatment of a postoperative wound infection after
saphenectomy of the great saphenous vein of the upper
left leg with the new antibiotic drug Daptomycin
(Cubicin®, Novartis Pharma Corporation, Germany).
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Case report
We report the case of a 68-year old man with severe, dif-
fuse coronary artery disease who presented with two
months of progressive angina-pectoris-symptoms. Coro-
nary angiography verified 3-vessel-disease with significant
stenoses of the main coronary branches (LAD 99%, RCX
80%, RCA 90%), moderately-decreased systolic left-ven-
tricular function and ST-elevations in leads II, III and aVF.
For these reasons, surgical revascularization was indi-
cated. The patient had a significant history of arterial
hypertension, Type II diabetes mellitus, adipositas, nico-
tine abuse (49 pack years), hypercholersterinemia and
performance of PTCA of the left coronary artery in 2002.
In the Department of Thoracic-, Cardiac- and Vascular
Surgery of the University of Goettingen, Germany, we per-
formed CABG with three single vein-grafts to the diagonal
branch (DB), right posterior descending artery (RPD) and
left posterolateral circumflex artery (LPL). The left anterior
descending artery (LAD) was revascularized by the left
internal mammarian artery (LIMA). Harvest of the saphe-
nous vein was performed by conventional open saphenec-
tomy harvest technique which involved an incision
extending from the left medial malleolus, along the
medial aspect of the knee to the groin.
During the patient's stay in the ICU, hemodynamic condi-
tions were stabilized and the patient was moved to a nor-
mal ward on second postoperative day. On 6th
postoperative day, after an uneventful mobilization, the
patient was suffering from pain in his leg and he devel-
oped a wound infection of the left upper leg. Saphenc-
tomy wound infection was presented with a large
dehiscence of 5 cm in diameter in the location where the
great saphenous vein had been harvested (Fig. 1). Clinical
laboratory parameters (Leucocytes and CRP) were signifi-
cantly increased and additionally to that, a wound swab
was taken from the infected site and a gram-positive Sta-
phylococcus epidermidis culture was indentified by the
Institute of Microbiology and Hygiene of the University of
Goettingen. The antibiogram presented methilin-resist-
ence as well as resistence to several conventional antibiot-
ics but displayed sensitivity to the new antibiotic drug
Daptomycin (Cubicin®, Novartis Pharma Corporation,
Germany). The drug was intravenously administered
(Dose: 4 mg/kg body weight) and total duration of dapto-
mycin-application was ten days. In addition, a VAC
sponge was placed to low continuous wall suction in
order to expedite the secondary wound healing process.
During this time clinical labor parameters decreased sig-
nificantly. Ten days later, another wound swab was taken
from the dehiscent wound but no microbiological culture
was identified. The wound was closed operatively and
healed secondarily without any further complications
(Fig. 2). An additional wound healing benefit was
revealed by application by VAC therapy in combination
with Daptomycin. The patient was discharged from hospi-
tal on the twenty-eighth postoperative day and was sent
for further rehabilitative therapy.
This case describes, to the best of our knowledge, the first
successful treatment of a saphenectomy wound infection
by the new antibiotic drug Daptomycin (Cubicin®,
Novartis Pharma Corporation, Germany) (Fig. 3). Further
research is required to evaluate the potential benefits of
this new antibiotic agent. Also, clinical, prospective and
Postoperative wound infection of the left upper limb six days  after CABG operation with conventional saphenectomy Figure 1
Postoperative wound infection of the left upper limb 
six days after CABG operation with conventional 
saphenectomy.
 
 
Left upper limb treated with wound infection treated by a  combination of vacuum-therapy and Daptomycin (Cubicin®,  Novartis Pharma GmbH, Germany) Figure 2
Left upper limb treated with wound infection treated 
by a combination of vacuum-therapy and Daptomy-
cin (Cubicin®, Novartis Pharma GmbH, Germany).
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randomized studies are necessary to compare several
treatment methods for saphenectomy wound infections
using different antibiotic drugs.
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Left upper limb after successful treatment of the wound  infection by Daptomycin (Cubicin®, Novartis Pharma GmbH,  Germany) Figure 3
Left upper limb after successful treatment of the 
wound infection by Daptomycin (Cubicin®, Novartis 
Pharma GmbH, Germany).
 